Novo Nordisk and Nanexa Sign €1.165 Billion Deal to Develop Longer-Acting Injections

Key Points

• Novo Nordisk has secured an exclusive global license to use Nanexa’s PharmaShell drug-delivery technology for certain peptide-based medicines.
• The collaboration covers up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditions.
• Monthly and quarterly dosing are target profiles, not established outcomes.
• Nanexa could receive up to €1.165 billion in upfront consideration and milestone payments, plus low single-digit royalties on future product sales.

Nanexa AB (publ) (NANEXA.ST) and Novo Nordisk (NYSE: NOVO) have signed a global license and collaboration agreement to develop long-acting injectable medicines that could be given less often. Novo will lead worldwide development and commercialization, while Nanexa will provide access to its PharmaShell platform for selected peptide drugs.

PharmaShell Targets Less Frequent Dosing

Nanexa’s PharmaShell technology applies an ultra-thin inorganic coating to individual drug particles. The coating is designed to control how an active ingredient is released over time.

The partners will explore injectable formulations with different dosing schedules, aiming for monthly and quarterly options. The announcement does not say that any product has achieved those schedules or reached the market.

Deal Includes Milestones and Royalties

Nanexa is eligible for payments totaling up to €1.165 billion. That figure includes €615 million across upfront consideration and potential development and regulatory milestones; the remainder consists of potential sales milestones. Nanexa may also receive low single-digit royalties on global net sales of products developed under the agreement.

The headline value is therefore a potential total, not an immediate payment to Nanexa. The companies did not specify how much of the €615 million is payable upfront.

Novo Will Lead Global Development

The agreement gives Novo an exclusive worldwide license to use PharmaShell in up to five programs involving certain peptide drugs for obesity, type 2 diabetes and other cardiometabolic indications.

For Nanexa, the deal expands the external use of its drug-delivery platform. For patients, the proposed benefit is a simpler treatment schedule—but whether the technology can deliver that benefit will depend on the results of future development.